+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

RNA Therapy Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028F

  • PDF Icon

    Report

  • 190 Pages
  • October 2023
  • Region: Global
  • TechSci Research
  • ID: 5893459
Free Webex Call
10% Free customization
Description Jump to:
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

 10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The Global RNA Therapy Clinical Trials Market recorded a valuation of USD 2.62 Billion in 2022 and is expected to experience substantial growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 5.06% and expected to reach USD 3.49 Billion through 2028. RNA therapy, a cutting-edge field of medical research, has emerged as a promising avenue for developing innovative treatments for a wide range of diseases. This novel approach harnesses the power of ribonucleic acid (RNA) to modulate gene expression and provide therapeutic benefits.

Market Overview:

The global RNA therapy clinical trials market has gained significant traction in recent years, revolutionizing the healthcare landscape and offering potential solutions for previously untreatable conditions. RNA therapy operates on the principle of utilizing RNA molecules, including messenger RNA (mRNA), small interfering RNA (siRNA), and antisense oligonucleotides (ASOs), to target specific genes and regulate their activity. This precision-based approach holds immense potential for addressing genetic disorders, infectious diseases, cancer, and even rare conditions that lack effective treatment options. Unlike traditional pharmaceuticals, RNA therapies aim to intervene at the genetic level, potentially providing more targeted and personalized treatments.

Key Market Drivers:

1. Rapid Advancement in RNA Technology:

Rapid advances in RNA technology have significantly propelled the Global RNA Therapy Clinical Trials Market, revolutionizing the landscape of medical research and healthcare. These breakthroughs are driving the development of innovative RNA-based therapies with the potential to address a wide spectrum of diseases and conditions.

2. Success of mRNA Vaccines:

The resounding success of mRNA vaccines has reverberated across the Global RNA Therapy Clinical Trials Market, catalyzing a paradigm shift in medical research and therapeutic development. The unprecedented achievements of mRNA vaccines have illuminated the immense potential of RNA-based therapies and spurred accelerated advancements in the field.

3. Technological Innovation:

Technological innovation stands as a driving force within the Global RNA Therapy Clinical Trials Market, ushering in transformative advancements that are reshaping the landscape of medical research and therapeutic development. These innovations span a range of areas critical to the success of RNA-based therapies and hold the potential to overcome challenges, enhance efficacy, and accelerate the translation of cutting-edge science into tangible clinical applications.

Key Market Challenges:

1. Delivery Challenges:

Delivery challenges are a critical aspect of the Global RNA Therapy Clinical Trials Market, representing a complex hurdle that researchers and developers must overcome to ensure the safe and effective administration of RNA-based therapies. These challenges center around the successful and targeted delivery of RNA molecules to specific cells or tissues within the body, a fundamental requirement for achieving the desired therapeutic outcomes.

2. Stability and Half-Life:

Stability and half-life are crucial considerations in the Global RNA Therapy Clinical Trials Market, playing a pivotal role in determining the effectiveness, safety, and practicality of RNA-based therapies. These factors directly impact the therapeutic potential of RNA molecules and their ability to deliver sustained and desired outcomes.

Key Market Trends:

1. Personalized and Precision Medicine:

Personalized and precision medicine represents a transformative approach within the Global RNA Therapy Clinical Trials Market, heralding a new era of tailored treatments that leverage individual genetic information to enhance therapeutic efficacy and minimize adverse effects.

2. Gene Editing Integration:

Gene editing integration represents a groundbreaking frontier within the Global RNA Therapy Clinical Trials Market, where the convergence of RNA-based therapies and advanced gene editing technologies is unlocking new avenues for targeted and precise interventions at the genetic level.

Segmental Insights:

Modality Insights:

In 2022, the RNA Therapy Clinical Trials Market was dominated by the messenger RNA segment, primarily due to the use of mRNA-based vaccinations and their potential in various disease states.

Phase Insights:

In 2022, the RNA Therapy Clinical Trials Market was dominated by phase II clinical trials, as they play a crucial role in determining the ideal dose and dosing regimen for RNA therapies.

Regional Insights:

In 2022, North America led the RNA Therapy Clinical Trials Market due to early adoption, robust research infrastructure, a favorable regulatory environment, and a strong biotechnology and pharmaceutical industry.

In conclusion, the Global RNA Therapy Clinical Trials Market is poised for significant growth, driven by rapid advancements in RNA technology, the success of mRNA vaccines, and ongoing technological innovations. While challenges such as delivery and stability must be addressed, the integration of personalized medicine and gene editing holds promise for reshaping the landscape of medical care and treatment.

Key Market Players

  • IQVIA
  • ICON Plc
  • Laboratory Corporation of America Holdings
  • Charles River Laboratories International, Inc.
  • PAREXEL International Corp.
  • Syneos Health
  • Medpace Holdings, Inc.
  • Novotech
  • Veristat, LLC.
  • Veristat, LLC.

Report Scope:

In this report, the Global RNA Therapy Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global RNA Therapy Clinical Trials Market, By Modality:

  • RNA interference
  • Antisense therapy Messenger RNA
  • Oligonucleotide
  • Non-antisense
  • Non-RNAi

Global RNA Therapy Clinical Trials Market, By Phase:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Global RNA Therapy Clinical Trials Market, By Therapeutic Area:

  • Rare Diseases
  • Anti-infective
  • Anticancer
  • Neurological
  • Alimentary/Metabolic
  • Musculoskeletal
  • Cardiovascular Respiratory
  • Sensory
  • Others

Global RNA Therapy Clinical Trials Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Singapore
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global RNA Therapy Clinical Trials Market.

Available Customizations:

Global RNA Therapy Clinical Trials Market report with the given market data, the publisher offers customizations according to a company's specific needs.


This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Types
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Global RNA Therapy Clinical Trials Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Modality (RNA interference, Antisense therapy, Messenger RNA, Oligonucleotide, non-antisense, non-RNAi)
5.2.2. By Phase (Phase I, Phase II, Phase III, Phase IV)
5.2.3. By Therapeutic Areas (Rare Diseases, Anti-infective, Anticancer, Neurological, Alimentary/Metabolic, Musculoskeletal, Cardiovascular Respiratory, Sensory, Others)
5.2.4. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
5.2.5. By Company (2022)
5.3. Product Market Map
5.3.1. By Modality
5.3.2. By Phase
5.3.3. By Therapeutic Areas
5.3.4. By Region
6. North America RNA Therapy Clinical Trials Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Modality
6.2.2. By Phase
6.2.3. By Therapeutic Areas
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States RNA Therapy Clinical Trials Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Modality
6.3.1.2.2. By Phase
6.3.1.2.3. By Therapeutic Areas
6.3.2. Canada RNA Therapy Clinical Trials Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Modality
6.3.2.2.2. By Phase
6.3.2.2.3. By Therapeutic Areas
6.3.3. Mexico RNA Therapy Clinical Trials Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Modality
6.3.3.2.2. By Phase
6.3.3.2.3. By Therapeutic Area
7. Europe RNA Therapy Clinical Trials Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Modality
7.2.2. By Phase
7.2.3. By Therapeutic Area
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany RNA Therapy Clinical Trials Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Modality
7.3.1.2.2. By Phase
7.3.1.2.3. By Therapeutic Area
7.3.2. France RNA Therapy Clinical Trials Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Modality
7.3.2.2.2. By Phase
7.3.2.2.3. By Therapeutic Area
7.3.3. United Kingdom RNA Therapy Clinical Trials Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Modality
7.3.3.2.2. By Phase
7.3.3.2.3. By Therapeutic Area
7.3.4. Italy RNA Therapy Clinical Trials Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Modality
7.3.4.2.2. By Phase
7.3.4.2.3. By Therapeutic Area
7.3.5. Spain RNA Therapy Clinical Trials Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Modality
7.3.5.2.2. By Phase
7.3.5.2.3. By Therapeutic Area
8. Asia-Pacific RNA Therapy Clinical Trials Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Modality
8.2.2. By Phase
8.2.3. By Therapeutic Area
8.2.4. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China RNA Therapy Clinical Trials Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Modality
8.3.1.2.2. By Phase
8.3.1.2.3. By Therapeutic Area
8.3.2. Japan RNA Therapy Clinical Trials Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Modality
8.3.2.2.2. By Phase
8.3.2.2.3. By Therapeutic Area
8.3.3. India RNA Therapy Clinical Trials Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Modality
8.3.3.2.2. By Phase
8.3.3.2.3. By Therapeutic Area
8.3.4. South Korea RNA Therapy Clinical Trials Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Modality
8.3.4.2.2. By Phase
8.3.4.2.3. By Therapeutic Area
8.3.5. Australia RNA Therapy Clinical Trials Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Modality
8.3.5.2.2. By Phase
8.3.5.2.3. By Therapeutic Area
9. South America RNA Therapy Clinical Trials Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Modality
9.2.2. By Phase
9.2.3. By Therapeutic Area
9.2.4. By Country
9.3. South America: Country Analysis
9.3.1. Brazil RNA Therapy Clinical Trials Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Modality
9.3.1.2.2. By Phase
9.3.1.2.3. By Therapeutic Area
9.3.2. Argentina RNA Therapy Clinical Trials Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Modality
9.3.2.2.2. By Phase
9.3.2.2.3. By Therapeutic Area
9.3.3. Colombia RNA Therapy Clinical Trials Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Modality
9.3.3.2.2. By Phase
9.3.3.2.3. By Therapeutic Area
10. Middle East and Africa RNA Therapy Clinical Trials Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Modality
10.2.2. By Phase
10.2.3. By Therapeutic Area
10.2.4. By Country
10.3. MEA: Country Analysis
10.3.1. UAE RNA Therapy Clinical Trials Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Modality
10.3.1.2.2. By Phase
10.3.1.2.3. By Therapeutic Area
10.3.2. Saudi Arabia RNA Therapy Clinical Trials Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Modality
10.3.2.2.2. By Phase
10.3.2.2.3. By Therapeutic Area
10.3.3. South Africa RNA Therapy Clinical Trials Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Modality
10.3.3.2.2. By Phase
10.3.3.2.3. By Therapeutic Area
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition
12.2. Product Development
12.3. Recent Developments
13. Clinical Trial Analysis
13.1. Ongoing Clinical Trials
13.2. Completed Clinical Trials
13.3. Terminated Clinical Trials
13.4. Breakdown of Pipeline, By Development Phase
13.5. Breakdown of Pipeline, By Status
13.6. Breakdown of Pipeline, By Study Type
13.7. Breakdown of Pipeline, By Region
13.8. Clinical Trials Heat Map
14. Competitive Landscape
14.1. Business Overview
14.2. Company Snapshot
14.3. Products & Services
14.4. Financials (As Reported)
14.5. Recent Developments
14.5.1. IQVIA
14.5.2. ICON Plc
14.5.3. Laboratory Corporation of America Holdings
14.5.4. Charles River Laboratories International, Inc.
14.5.5. PAREXEL International Corp.
14.5.6. Syneos Health
14.5.7. Medpace Holdings, Inc.
14.5.8. Novotech
14.5.9. Veristat, LLC.
14.5.10. Veristat, LLC.
15. Strategic Recommendations

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • IQVIA
  • ICON Plc
  • Laboratory Corporation of America Holdings
  • Charles River Laboratories International, Inc.
  • PAREXEL International Corp.
  • Syneos Health
  • Medpace Holdings, Inc.
  • Novotech
  • Veristat, LLC.
  • Veristat, LLC.

Table Information

Report AttributeDetails
No. of Pages190
PublishedOctober 2023
Forecast Period2023 - 2028
Estimated Market Value ( USD ) in 2023 $ 2.62 Billion
Forecasted Market Value ( USD ) by 2028 $ 3.49 Billion
Compound Annual Growth Rate5.0%
Regions CoveredGlobal

Related Topics

Related Reports

Global Messenger RNA (mRNA)-based Vaccines and Therapeutics - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Global Messenger RNA (mRNA)-based Vaccines and Therapeutics - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Global Messenger RNA - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Global Messenger RNA - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
RNA-based Therapeutics Market - Product Image

RNA-based Therapeutics Market

  • Report
  • 200 Pages
  • Global
From
RNA Editing Technologies Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F - Product Image

RNA Editing Technologies Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
RNA Therapy Market by Technology, Indication, End User - Global Forecast 2025-2030 - Product Image

RNA Therapy Market by Technology, Indication, End User - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From

About the Market

RNA Therapy Clinical Trials are a form of gene therapy that uses RNA molecules to treat diseases. RNA molecules are used to deliver genetic material to cells, which can then be used to modify the expression of a gene or to replace a mutated gene. This type of therapy has been used to treat a variety of diseases, including cancer, cardiovascular disease, and neurological disorders. RNA Therapy Clinical Trials involve the use of a variety of technologies, such as gene editing, gene silencing, and gene delivery. These technologies are used to modify the expression of a gene or to replace a mutated gene. The goal of these trials is to determine the safety and efficacy of the therapy. Companies involved in the RNA Therapy Clinical Trials market include Editas Medicine, Intellia Therapeutics, CRISPR Therapeutics, and Moderna Therapeutics. These companies are focused on developing therapies that use RNA molecules to treat a variety of diseases. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.